Limitations of genome-wide approaches for genetically-heterogenous orphan diseases led us to develop a new approach to identify novel Emery-Dreifuss muscular dystrophy (EDMD) candidate genes. We generated a primer library to genes: (I) linked to EDMD, (II) mutated in related muscular dystrophies, (III) highlighted from limited exome sequencing, (IV) encoding muscle-specific nuclear membrane proteins. Sequencing 56 unlinked EDMD patients yielded confirmed or strong candidate alleles from all categories, accounting for most remaining unlinked patients. Known functions of newly-linked genes argue the EDMD pathomechanism is from altered gene regulation and mechanotransduction through connectivity of candidates from the nuclear envelope to the plasma membrane.
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Results
SEQUENCING EDMD FAMILIES
Whole exome sequencing was performed in 12 EDMD patients and 12 unaffected individuals from 5 families with large enough pedigrees for linkage analysis (Fig. 1) , finding over 250,000 variants compared to the reference sequence. Variants were filtered using criteria: (a) phenotype co-segregation and modes of inheritance for each family; (b) selecting for SNP frequencies <1%, and filtering for <0.05%; (c) affecting coding sequence; (d) function/tissue-expression of the encoded protein e.g. >2-fold higher expression in muscle compared to other tissues. Filtering yielded 213 candidate genes for families [2] [3] [4] [5] ( Supplemental Table S1 ).
Family 1 yielded no convincing candidates. As this family had the largest pedigree, we postulated that an unaffected individual was a carrier who had not yet presented or had a distinct sporadic form of disease. Dropping younger individuals who may have not yet presented clinically failed to yield candidates; therefore, genome and transcriptome sequencing was performed in the index patient, resulting in 33 additional candidates ( Supplemental Tables S2 and S3 ). The combined exome, genome and RNA sequencing yielded a total of 252 candidates for the five families.
PRIMER LIBRARY SEQUENCING
A primer library was generated containing (I) the 8 previously-linked EDMD gene ORFs plus the whole genes for LMNA and EMD (that together account for ~40% of linked alleles), (II) 25 genes from similar muscular dystrophies, (III) the 252 exome sequencing candidates, and (IV) 16 functional candidates, mostly muscle-specific nuclear envelope proteins ( Fig. 2A ; Supplemental Table S4 ). Sequencing was performed on 56 additional 7/41 unlinked clinically diagnosed EDMD patients unrelated to each other, obtaining on average 3,427,092 reads per patient. The data were analyzed for genes carrying mutations that changed the coding sequence (nonsense, missense, splice sites) with expected altered protein function (e.g. non-conservative substitutions) and SNP frequencies <0.05% (Supplemental Table S5 ).
Candidate mutations were found in all four categories. Of category I previous EDMDlinked genes, LMNA had mutations in three patients that were missed in standard diagnostics (p.R41H, p.R249Q, p.G535fs*; Table 1 ). These mutations were determined as causative based on similarity to previously linked LMNA mutations. Previously EDMD-associated genes SYNE1, SYNE2, SUN1 and TMEM43 also had mutations; however, minor allele frequencies and their combination with other mutations made them unlikely as causative alleles excepting SYNE1. Modifying effects, nonetheless, cannot be excluded. No mutations were found in LMNA or EMD non-coding regions.
Gene category II of related muscular dystrophies yielded 18 patients with mutations considered causative. Four of these patients had combinations of a missense and frameshift mutation in CAPN3 (Table 1) . GBE1 mutations were found in four other patients: three missense and one splice-site. VCP and likely recessive TTN were mutated in two patients each; however, TTN mutation patients also carried SYNE1 mutations. Genes with one patient carrying likely disease-causing mutations were COL6A1, CAV3, DMD, ANO5, DYSF and POMT1. The DMD mutation created a stop codon at codon three, resulting in possible usage of an alternative start codon and a milder phenotype than Duchenne 26 . For ANO5, DYSF and POMT1 the respective patients had two mutations, consistent with the reported inheritance (autosomal recessive for MD-20/ANO5 and unknown for MD-21/DYSF and MD-23/POMT1; Table 1 ). However, lacking DNA from the parents we could not perform segregation studies.
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Several category III genes from exome sequencing were elevated to strong candidates if mutated in multiple patients within the primer library cohort based on the assumption that causative genes will be independently mutated in multiple patients. The top candidates were INTS1, ANK2, XIRP1 and USP34. Heterozygous ANK2 mutations were identified in family 5 plus six cohort patients with no other obvious disease-causing mutations and so were most likely causative ( Table 2 ). Causation is similarly likely for other genes; however, in some patients there were additional candidate alleles identified. Heterozygous INTS1 was mutated in four members of family 3 plus five cohort patients, four of whom had no mutation in already associated genes ( Table 2 ). The last patient, MD-23, additionally carried two POMT1 mutations; however, it is unclear if the likely recessive POMT1 mutations affected one allele or both so causation remains undetermined. Other good category IV candidates were USP34 (heterozygous mutations in exome sequenced family 2) and XIRP1 (mutated in families 2 and 4), each with mutations in an additional five patients. Some patients had additional mutations in already associated genes, but if these other mutations were causative then modifying effects for the new candidates are still possible.
Several category IV functional/tissue candidate genes were mutated in 16 of the 56 primer library cohort patients. These were WFS1 (4 patients), TMEM201 (3 patients), TMEM38A (3 patients), PLPP7 (2 patients), TMEM214 (2 patients), LPCAT3 (1 patient), KLHL31 (1 patient), and BVES (1 patient). Of these, three patients with TMEM38A mutations, two patients with TMEM214 mutations, one patient with an LPCAT3 mutation and one patient with a BVES mutation were clearly the top candidates with no other reasonable candidates identified and patient MD-32 carried mutations in both TMEM38A and PLPP7. Other mutations identified were in association with other possible candidates that included likely causative mutations in GBE1, COL6A1, LMNA and TTN (details in Table 1 ). The patient with the combined LMNA and TMEM201 mutations had a very early age of onset (1 year), 9/41 suggesting that both mutations contribute to the more severe (congenital) phenotype as the LMNA mutation has not been associated with congenital muscular dystrophy.
All in all, sequencing the 56 additional patients with the primer library found mutations in only a subset of the 252 candidates from the exome sequencing and this subset is expected to be much higher confidence because causative genes are more likely to be also mutated in other EDMD patients. In contrast, mutations were found in 19 of 25 related muscular dystrophies and in 11 of 16 functional candidates; so a strong enrichment for these candidate pools was observed ( Fig. 2A ).
NUCLEAR ENVELOPE LINKS
All previously linked EDMD genes encode nuclear envelope proteins. The functional candidates were also biased towards genes identified in the nuclear envelope by proteomics; however, there was no bias towards the nuclear envelope when selecting genes for the primer library from similar muscular dystrophies or from exome sequencing. Nonetheless, the majority of genes from similar muscular dystrophies encode proteins for which at least a subpopulation associates with the nuclear envelope ( Fig. 2B ). Interestingly, just considering the candidates from the exome sequencing in which mutations were also found in other patients from the primer library sequencing, the nuclear envelope portion increased from less than 10% to more than 40% -considerable more than the overall genome portion of 5.9% ( Fig. 2B ). Of note, the proteins encoded by genes linked to other muscular dystrophies such as COL6A1, CAV3, DYSF, DMD, TTN, and VCP and the strongest family sequencing candidates INTS1 and ANK2 were all found in nuclear envelope proteomics datasets 20,27 . While these could reflect either a separate pool in the nuclear envelope or connections that were maintained during nuclear envelope isolation, this suggests at least an indirect physical connection of these candidates to the nuclear envelope.
10/41
The two top argued mechanisms for how mutations in nuclear envelope proteins can cause pathology are mechanical instability and genome misregulation. Genes in different candidate categories contained Gene Ontology (GO)-terms for functions in gene regulation, cytoskeleton, and both together. Interestingly, the likely candidates from all categories were enriched for genes simultaneously linked to both gene regulation and cytoskeleton GO-terms compared to the overall genome ( Fig. 2C ). Such genes may be involved in mechanosignal transduction to the genome. Consistent with this idea, most of the proteins encoded by the final candidate genes interact with other candidates according to interactome studies and these interactions form a chain of connectivity between the nuclear envelope and the plasma membrane via cytoskeletal proteins that could support mechanotransduction to the genome ( Fig. 2D ).
CONFIRMATION OF NOVEL EDMD ALLELES
Thus far only the three LMNA mutations, the CAV3 and one of the CAPN3 (MD- 43) mutations have been confirmed as insufficient numbers of family members have come to clinic for linkage analysis. Therefore, to test the likelihood that other mutations identified cause EDMD disease pathology, we tested two of the gene regulating NETs to determine if the mutations identified disrupt their normal functions in myogenic gene regulation. In keeping with this idea, for the 8 out of 16 functional NET candidates where mutations were found (6 of which have known gene regulation functions), nearly all mutations identified faced the nucleoplasm or were positioned where they could alter membrane topology (Fig.   3A ). The two muscle-specific NETs we chose to test were PLPP7/NET39 and Tmem38A.
Both recruit partially overlapping, but mostly different sets of genes to the nuclear periphery to enhance their repression and many of the genes targeted are antagonistic to myogenesis or from alternate differentiation pathways 24 . Combined knockdown of PLPP7/NET39, 11/41 TMEM38A and WFS1 blocked myogenesis, providing a logical route from their disruption to muscle disease pathology. Therefore, the PLPP7 and TMEM38A mutations were exogenously expressed in C2C12 myoblast cells to determine if they could perform the previously shown gene positioning function of the wild-type in recruiting specific gene targets to the nuclear periphery for enhanced repression. Tmem38A normally repositions the DDR2 gene locus to the nuclear envelope to repress it during myogenesis, but with mutations p.N260D and p.N260del it fails to do so ( Fig. 3B) . Similarly, PLPP7/NET39 normally recruits the PTN gene locus to the nuclear envelope to repress it during myogenesis, but with mutation p.R252P it could not. PLPP7/NET39 mutation p.M92K also affected the gene positioning, though apparently in the opposite direction which might also affect expression ( Fig. 3C ).
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Discussion
Failure of high throughput genomic approaches to identify new disease alleles can at least in some cases be overcome by our multistage approach. This approach pinpointed candidates in part based on the preferential tissue focus of pathology and in part on the subcellular localization of known alleles. Similarly applying filters in focusing candidates for such a multipronged approach can be applied to other genetically heterogeneous diseases.
With nearly half of EDMD cases previously linked to genes encoding 6 nuclear envelope proteins it was clear that EDMD is a nuclear envelope disease. This is strengthened by enrichment for nuclear envelope proteins amongst our top new candidate alleles. COL6A1, CAV3, DYSF, DMD, TTN, and VCP gene products were found in muscle nuclear envelopes 20 .
As most of these proteins have previously been associated with the cytoskeleton or plasma membrane, their association with the nuclear envelope may be indirect through lamincytoskeletal connections. However, this association could also be due to splice variants that target to the nuclear envelope or specific translocation to the nucleus under certain conditions as has been shown for CAV3 family member caveolin 2. In this case, a caveolin 2 subpopulation translocates to the nucleus and interacts with lamin A to regulate histone modifications and gene expression 28 .
The gene positioning defects for TMEM38A and PLPP7 mutations not only further link the nuclear envelope to EDMD, but also strengthen the idea that misregulation of myogenic gene expression is the primary cause of EDMD pathology. In addition to Tmem38A and Plpp7, the muscle NETs Tmem214, WFS1, and NET5/Samp1 all have generepositioning functions that contribute to gene regulation and the NET MAN1 affects gene regulation through its interactions with Smads as well as binding several chromatin partners 29,30 . The involvement of these muscle gene repositioning NETs, not only as novel causative alleles but also in mediating EDMD pathology caused by mutations in widely 13/41 expressed nuclear envelope proteins, is further supported by WFS1, Tmem214, Tmem38A, and NET5/Samp1 being mislocalized in isolated differentiating EDMD muscle cells or muscle biopsy sections 31 .
Of the previously EDMD-linked nuclear envelope proteins, Lamin A has both cytoskeletal and genome regulation functions; so its mutation could support both mechanical instability and genome misregulation hypotheses for EDMD pathophysiology 32-37 . Emerin interacts with actin supporting a cytoskeletal role, but it also has many reported contributions to genome regulation through its binding DNA condensing factors BAF and HDAC3, splicing factors, the transcription factor Lmo7, and the transcriptional repressor germ cell-less 38 . FLH1 is linked to signal transduction and splice variant FHL1B targets specifically to the nuclear envelope 39 . Moreover, FHL1 has been linked to other myopathies such as X-linked myopathy with postural muscle atrophy (XMPMA) 40 via its signal transduction function.
As signaling functions could affect both gene regulation and the cytoskeleton, these mechanisms toward pathology were considered equally likely; however, a gene misregulation mechanism is much more likely now with the new gene-repositioning candidate alleles identified. Though there are some other disparate functions reported for several of these NETs 20,22,41 , WFS1, Tmem38A/TRIC-A, NET39/ PLPP7, Tmem214 and NET5/Samp1 are all at the nuclear envelope preferentially in muscle and all share a common function in directing gene-repositioning for regulation of gene expression during myogenesis 24 . That some of these muscle-specific NETs had overlap in their functions further supports the possibility of their working in a common pathway towards EDMD pathophysiology. At the same time, while there was some overlap in the sets of genes regulated by these muscle NETs, each had also unique gene targets. The links of candidate alleles to gene repositioning and mechanotransduction are the more compelling in this context because the different sets of 14/41 genes regulatedall important in myogenesisthus supports the clinical variation observed in EDMD.
Our sequencing in patients diagnosed with an EDMD-like phenotype identified mutations in several genes linked to muscular dystrophies that share clinical features with EDMD. This might reflect incorrect diagnoses or their involvement in EDMD. The latter case seems likely, considering that COL6A1, CAV3, DYSF, DMD, TTN, and VCP gene products link to the nuclear envelope. Indeed, many of these gene products interact with one another in a way that could form a chain from the plasma membrane to the nuclear envelope ( Fig. 2D ).
This also is compelling to this gene regulation mechanism as this chain could play a role in mechanosignal transduction to the nucleus.
Finally, as the families chosen for exome sequencing all had differences in presentation, there are likely additional mutations picked up in the primer library that eventually might be used as predictors of severity or other aspects of clinical presentation once further sequencing reveals better correlations. Thus it would be beneficial to continue using this primer library diagnostically both to find these correlations and because it is cheaper and faster than standard iterative Sanger sequencing for such a genetically variable disease to identify mutations in known linked genes. In general, this iterative multipronged approach, combining into a primer library a set of preliminary candidates from exome sequencing in which only sufficient pedigrees exist for partial linkage analaysis together with candidates from related disorders and candidates specific to the tissue where pathology is manifested that are associated with linked organelles and functions, might be applied to a wider range of genetically heterogeneous orphan diseases where insufficient numbers of patients are available for standard genome and exome approaches to be effective.
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Exome: Sequencing was performed on the Illumina HiSeq and raw data processed with CASAVA 1.8.
FLUORESCENCE IN SITU HYBRIDIZATION
Mutations were generated by Agilent Site-Directed mutagenesis. Plasmids encoding tagged Tmem38a, PLPP7 and mutants were transfected using Lipofectamine 3000 (Invitrogen) into C2C12 cells (ATCC, VA, USA) cultured at 37°C, 5% CO2 in DMEM containing 20% FBS, 50U/mL penicillin and 10mg/mL streptomycin. Fluorescent in situ hybridization (FISH) experiments were performed as described in 42 . 
PRIMER LIBRARY CONSTRUCTION, PROCESSING AND SEQUENCING
BIOINFORMATICS
Variant analysis was performed using the Genome Analysis toolkit [GATK] v2.7-2 43 and picard tools v1.74 (http://broadinstitute.github.io/picard/) using GATK Best Practices recommendations 44, 45 against human genome assembly hg19. The allele frequencies of variants were cross-referenced with gnomAD version 2.1 46 using both the genome and exome datasets.
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RNA-Seq: STAR v2.1.1 47 was used to map reads to the hg19 reference genome, samtools v0.1.19 48 was used for file conversion. Deeptools v1.5.1 49 was used for downstream analysis.
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Light green: known disease associated genes (EDMD or similar MDs) with unlikely disease causing mutation or two genes of similar likelihood to be the causative disease allele (category 2 and 3).
Yellow: functional candidate gene mutations (category 1).
Purple: mutations in genes from the family sequencing (category 4). Light green: known disease associated genes (EDMD or similar MDs) with unlikely disease causing mutation or two genes of similar likelihood to be the causative disease allele (category 2 and 3).
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Purple: mutations in genes from the family sequencing (category 4). 
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